Test Code LAB9336 Acetylcholine Receptor Modulating Antibody, Flow Cytometry Assay, Serum
Additional Codes
ACMFS
Ordering Guidance
Typically, physicians will order acetylcholine receptor (AChR) binding, blocking, and modulating antibodies. Mayo Clinic Laboratories' (MCL) tests are not named in that manner; instead these are offered as myasthenia gravis (MG) evaluations. MGMR / Myasthenia Gravis Evaluation with Muscle-Specific Kinase (MuSK) Reflex, Serum is the testing of choice in most cases.
AChR blocking antibody testing is no longer offered individually as it offers no added-value to the diagnosis and management of MG.
Specimen Required
Only orderable as part of a profile. For more information see:
MGLE / Myasthenia Gravis/Lambert-Eaton Myasthenic Syndrome Evaluation, Serum
MGMR / Myasthenia Gravis Evaluation with Muscle-Specific Kinase (MuSK) Reflex, Serum
PAVAL / Paraneoplastic, Autoantibody Evaluation, Serum
Collection Container/Tube:
Preferred: Red top
Acceptable: Serum gel
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Secondary ID
610029Useful For
Diagnosis for autoimmune myasthenia gravis (MG) in adults and children
Distinguishing autoimmune from congenital MG in adults and children or other acquired forms of neuromuscular junction transmission disorders.
This test is a qualitative assay and should not be used for monitoring purposes.
Method Name
Only orderable as part of a profile. For more information see:
MGLE / Myasthenia Gravis/Lambert-Eaton Myasthenic Syndrome Evaluation, Serum
MGMR / Myasthenia Gravis Evaluation with Muscle-Specific Kinase (MuSK) Reflex, Serum
PAVAL / Paraneoplastic, Autoantibody Evaluation, Serum
Flow Cytometry
Specimen Type
SerumSpecimen Minimum Volume
0.5 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 28 days | |
Frozen | 28 days | ||
Ambient | 72 hours |
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Reference Values
Only orderable as part of a profile. For more information see:
MGLE / Myasthenia Gravis/Lambert-Eaton Myasthenic Syndrome Evaluation, Serum
MGMR / Myasthenia Gravis Evaluation with Muscle-Specific Kinase (MuSK) Reflex, Serum
PAVAL / Paraneoplastic, Autoantibody Evaluation, Serum
Negative
Interpretation
This assay shows strong qualitative concordance with the previous modulating assay.
Positive results in this antibody evaluation are indicative of autoimmune myasthenia gravis (MG). These results should be interpreted in the appropriate clinical and electrophysiological context.
The presence of acetylcholine receptor (AChR) modulating antibodies along with AChR binding antibodies as compared to AChR binding antibodies alone, improves the diagnostic accuracy for MG.
In the presence of AChR modulating antibodies, a paraneoplastic basis should be considered with thymoma being the most commonly associated tumor with MG.
Negative results do not exclude the diagnosis of MG. If clinical suspicion remains and symptoms persistent or worsen consider re-testing.
Method Description
This method uses flow cytometry to measure the loss of acetylcholine receptors (AChR) expressed on the surface of live cells. The cell line used is an immortalized human rhabdomyosarcoma cell line that expresses endogenous muscle-type nicotinic AChR on its surface. Cells are plated in a 96-well plate and cultured prior to the addition of patient serum, which is then incubated on the cells to enable antibody-mediated internalization of AChR (modulation).
Subsequently, modulation is then stopped and the amount of AChR on the cell surface is measured by flow cytometry. The detection of receptors is performed using a recombinant rat monoclonal antibody specific for the human alpha-subunit of the AChR followed by a secondary goat anti-rat IgG antibody conjugated with allophycocyanin (APC). The amount of AChR on the cell surface is proportional to the median fluorescence intensity (MFI) of APC. To calculate the amount of modulation (ie, % loss of AChR), the APC MFI is compared between cells treated with patient serum and cells treated with serum lacking AChR modulating antibodies. Background signal is established in each experiment utilizing cells stained with secondary antibody alone (no patient sera). The percent loss of AChR is calculated as 1-([Patient MFI-Background MFI]/[Negative calibrator MFI-Background MFI]*100%).(Unpublished Mayo method)
Day(s) Performed
Monday, Wednesday, Saturday
Report Available
5 to 8 daysSpecimen Retention Time
28 daysPerforming Laboratory
Mayo Clinic Laboratories in RochesterCPT Code Information
86043
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
ACMFS | AChR Modulating Flow Cytometry, S | 99062-2 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
610029 | AChR Modulating Flow Cytometry, S | 99062-2 |